DoubleChecks

What was claimed

IVERMECTIN & MEBENDAZOLE should be sold over-the-counter and available to everyone. New study shows 84.4% Clinical Cancer Benefit — Nearly 50% Report Cancer Disappearance. We could be CURING your wife, your husband, your parents & your children.

Our verdict

Inaccurate

Ivermectin and mebendazole are regulated prescription or controlled medicines in many jurisdictions and are not generally approved over-the-counter for cancer treatment. Current oncology and regulatory guidance explicitly advises against using ivermectin or similar antiparasitics for cancer outside clinical trials. Authoritative sources, including oncology reviews and regulatory and fact-checking organizations, state there is no robust clinical evidence that ivermectin or mebendazole cure cancer in humans or provide proven survival benefit. Calling these drugs a cure overstates preliminary, hypothesis-generating data and contradicts current expert consensus.

All 3 AI systems agree15 sources citedChecked Aug 27, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

Ivermectin & mebendazole should be sold over‑the‑counter and available to everyone because they cure cancer (we could be curing your family).

Incorrect93%
2 of 3 AIs agree·Claude: Misleading

We could be CURING your wife, your husband, your parents & your children.

Incorrect95%
All 2 AIs agree

The study demonstrates these drugs are effective cancer treatments

Misleading90%
1 AI checked

New study shows 84.4% Clinical Cancer Benefit — Nearly 50% Report Cancer Disappearance.

Misleading91%
2 of 3 AIs agree·Claude: Verified

Nearly 50% report cancer disappearance (tumor regression or no current evidence of disease).

Verified95%
1 of 2 AIs agree·ChatGPT: Misleading

Verified against 15 sources

expose-news.compubmed.ncbi.nlm.nih.govyahoo.comtwg.healththerealfacthunter.comjillcarnahan.comsanarelab.scienceifmsynergy.comfactcheck.afp.comx.comdrugs.comx.comx.compmc.ncbi.nlm.nih.govpccarx.com

Detailed Analysis

The statement promotes ivermectin and mebendazole as over-the-counter cancer cures, which is not supported by current medical evidence or regulatory guidance. The cited 84.4% clinical benefit figure comes from a highly limited observational study and does not justify claims of curing cancer or broad OTC use.

Why this verdict

  • The statement promotes ivermectin and mebendazole as over-the-counter cancer cures, which is not supported by current medical evidence or regulatory guidance.
  • The cited 84.4% clinical benefit figure comes from a highly limited observational study and does not justify claims of curing cancer or broad OTC use.

Claims checked

IVERMECTIN & MEBENDAZOLE should be sold over-the-counter and available to everyone.

Incorrect90%
Ivermectin and mebendazole are regulated prescription or controlled medicines in many jurisdictions and are not generally approved over-the-counter for cancer treatment. Current oncology and regulatory guidance explicitly advises against using ivermectin or similar antiparasitics for cancer outside clinical trials.

This claim may mislead readers without added context.

We could be CURING your wife, your husband, your parents & your children.

Incorrect95%
Authoritative sources, including oncology reviews and regulatory and fact-checking organizations, state there is no robust clinical evidence that ivermectin or mebendazole cure cancer in humans or provide proven survival benefit. Calling these drugs a cure overstates preliminary, hypothesis-generating data and contradicts current expert consensus.

This claim may mislead readers without added context.

New study shows 84.4% Clinical Cancer Benefit — Nearly 50% Report Cancer Disappearance.

Misleading90%
A 2026 observational cohort study reported an 84.4% 'clinical benefit ratio' with about 48.4% of participants self-reporting no evidence of disease or tumor regression. However, the study is uncontrolled, relies heavily on self-reported data, and experts and fact-checkers state it cannot demonstrate that ivermectin or mebendazole improve cancer outcomes or cure cancer.

This claim may mislead readers without added context.

What other AI think

The claim misrepresents a real observational study by presenting preliminary findings as definitive cancer cures. While the 84.4% clinical benefit ratio and ~48% cancer disappearance figures are accurate, the study explicitly states these are self-reported outcomes requiring randomized controlled trials for validation. The claim that these drugs "could be CURING" people is dangerously misleading given the lack of FDA approval and high-quality clinical evidence.

Why this verdict

  • The claim misrepresents a real observational study by presenting preliminary findings as definitive cancer cures.
  • While the 84.4% clinical benefit ratio and ~48% cancer disappearance figures are accurate, the study explicitly states these are self-reported outcomes requiring randomized controlled trials for validation.
  • The claim that these drugs "could be CURING" people is dangerously misleading given the lack of FDA approval and high-quality clinical evidence.

Claims checked

We could be CURING your wife, your husband, your parents & your children

Incorrect95%
No high-quality clinical evidence shows these drugs cure cancer in humans. The study authors explicitly state findings are 'hypothesis-generating' and call for randomized controlled trials. FDA has not approved either drug for cancer, and preliminary data show no significant benefit in some trials.

This claim may mislead readers without added context.

IVERMECTIN & MEBENDAZOLE should be sold over-the-counter

Misleading90%
Neither drug is FDA-approved for cancer treatment. Ivermectin is approved only for parasitic infections; mebendazole is approved only for parasitic infections. Making them OTC for cancer would bypass regulatory safety requirements for a non-approved indication.

This claim may mislead readers without added context.

The study demonstrates these drugs are effective cancer treatments

Misleading90%
The study is observational with self-reported outcomes, potential selection bias, and uncontrolled confounding. Most participants received concurrent conventional therapies (chemotherapy 27.9%, radiation 21.3%, surgery 19.7%), making it impossible to attribute outcomes to ivermectin/mebendazole alone.

This claim may mislead readers without added context.

The numerical figures (84.4% and ~50%) do appear in a recently published prospective, real‑world, observational cohort. However those results are self‑reported, unverified, from a nonrandomized study with major methodological limitations and do not demonstrate that these drugs cure cancer. Presenting the numbers as proof that ivermectin and mebendazole 'cure' cancer is misleading and dangerous.

Why this verdict

  • The numerical figures (84.4% and ~50%) do appear in a recently published prospective, real‑world, observational cohort.
  • However those results are self‑reported, unverified, from a nonrandomized study with major methodological limitations and do not demonstrate that these drugs cure cancer.
  • Presenting the numbers as proof that ivermectin and mebendazole 'cure' cancer is misleading and dangerous.

Claims checked

Ivermectin & mebendazole should be sold over‑the‑counter and available to everyone because they cure cancer (we could be curing your family).

Incorrect95%
There is no high‑quality randomized clinical trial or regulatory approval showing these drugs cure cancer; recommending OTC availability and claiming they cure people is not supported by current evidence and is potentially harmful.

This claim may mislead readers without added context.

A new study shows 84.4% Clinical Cancer Benefit for ivermectin + mebendazole.

Misleading92%
An observational prospective cohort reported a self‑reported Clinical Benefit Ratio of 84.4% at six months, but the outcome data were patient‑reported, not independently verified, and the study design cannot establish efficacy.

This claim may mislead readers without added context.

Nearly 50% report cancer disappearance (tumor regression or no current evidence of disease).

Misleading92%
The study reported roughly 46–50% of participants self‑reporting either regression or 'no current evidence of disease', but these are unverified, heterogeneous cases and do not constitute proof of tumor eradication.

This claim may mislead readers without added context.

Share this result

Try DoubleChecks